Overview

An Open-label Phase I Study of Orally Available Novel Small-molecule Fibroblast Growth Factor Receptors (FGFR) 1,2,3 and 4 Inhibitor, ASP5878 at Single and Multiple Doses in Patients With Solid Tumors

Status:
Completed

Trial end date:
2017-07-19

Target enrollment:

Participant gender:

Summary

The objectives of this study are to determine the tolerability, safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of oral ASP5878 in participants with solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

Astellas Pharma Inc

Collaborator:

Astellas Pharma Global Development, Inc.